MedTrace Logo

Omalizumab in the Treatment of Peanut Allergy

NCT00949078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2017-07-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.

Conditions

Interventions

DRUG

omalizumab

omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE

Sponsors & Collaborators

Principal Investigators

  • Robert A Wood, MD · Johns Hopkins University

  • Sarbjit Saini, MD · Johns Hopkins University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949078 on ClinicalTrials.gov